Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP-1 asset BT-001 into late-stage development, with two trials planned this ...

With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously ...

In life sciences manufacturing, inspections by the FDA, state regulators or other agencies are part of the job. But too often ...

Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...

Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis ...

Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...

Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging ...

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.